戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1           Advanced Accelerator Applications (Novartis).
2 al Research, which is the research engine of Novartis.
3 ugh Spark Therapeutics and worldwide through Novartis.
4 ncer Research UK, Target Ovarian Cancer, and Novartis.
5 mistry programmes pursued at AstraZeneca and Novartis.
6 spitals, French Society of Rheumatology, and Novartis.
7 titute, Korea Health Technology R&D Project, Novartis.
8 been optimized to clinical candidates by GNF/Novartis.
9 g Foundation, Roche Diagnostics, Pfizer, and Novartis.
10 art Foundation, UK Medical Research Council, Novartis.
11 fficacy >70%) in a large siRNA data set from Novartis.
12 alition), Breast Cancer Research Foundation, Novartis.
13 1 R132H by Ivosidenib and another inhibitor, Novartis 224, is readily resolved as a two-stage process
14 17 ((177)Lu-vipivotide tetraxetan, Pluvicto, Novartis/AAA) was approved on March 23, 2022, based on t
15 mithKline) and 5-HT type 4 agonist (Zelnorm, Novartis, AB) drugs on the dynamics of bolus progression
16                                              Novartis Access had little effect in its first year in K
17                   We evaluated the effect of Novartis Access in Kenya, the first country to receive t
18                                              Novartis Access is a Novartis programme that offers a po
19 t health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential
20                                              Novartis Access significantly increased the availability
21 ith or without MF59 (registered trademark of Novartis AG) adjuvant (an oil-in-water emulsion).
22                   University of Pennsylvania-Novartis Alliance and NIH.
23 s received the H1N1 vaccine (15-microg dose; Novartis), and antibody titers at baseline and after imm
24 ions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepracor.
25 ions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepracor; GlaxoSmithKline; Centers for Med
26 by project partners Chiesi, Grifols, Insmed, Novartis, and Zambon.
27 ly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor
28 Although imatinib mesylate (STI571, Gleevec, Novartis, Basal, Switzerland) produces high rates of com
29 in-1-yl]phenyl} propanenitrile (NVP-BEZ235) (Novartis, Basel Switzerland), a dual phosphatidylinosito
30 successfully with a targeted drug, imatinib (Novartis, Basel).
31 antibodies (IL-2RAs): basiliximab (Simulect; Novartis, Basel, Switzerland) and daclizumab (Zenapax; R
32 oup C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerland) and sirolimus with target
33 nhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable effic
34 transplant recipients receiving CsA (Neoral; Novartis, Basel, Switzerland).
35 eutic targets of imatinib mesylate (Gleevec; Novartis, Basel, Switzerland).
36     The study was developed and conducted by Novartis Biomedical Research (Cambridge, MA, USA).
37 with higher selectivity as recently shown by Novartis but that there is little compelling reason to e
38  complex, LCZ696, developed by scientists at Novartis, combines an angiotensin receptor blocker with
39  Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and Techno
40         Advanced Accelerator Applications, a Novartis company.
41         Advanced Accelerator Applications, a Novartis Company.
42  high-throughput phenotypic screen using the Novartis compound library and identified candidate chemi
43                                      Jansen: Novartis: Consultancy, Other: Travel, Accommodations, Ex
44              Comparing the CHEMBL results to Novartis data, we find that significant transformation e
45 th the histone deacetylase inhibitor LBH589 (Novartis) depletes Bcr-Abl levels.
46 sel, Switzerland), and cyclosporine (Neoral, Novartis, East Hanover, NJ).
47 asmin (Jetrea, Thrombogenics Inc, USA, Alcon/Novartis EU).
48 e to pollen from a Bt corn hybrid containing Novartis event 176 on two species of Lepidoptera, black
49 paring the observed RPE gene profiles to the Novartis expression database (SymAtlas) of 78 tissues.
50 ons, who underwent leukapheresis shipment to Novartis for commercial tisagenlecleucel.
51 not inferior to deferoxamine (DFO; Desferal, Novartis) for the removal of cardiac iron in beta-thalas
52                                              Novartis Foundation, Bill & Melinda Gates Foundation, an
53            An X-ray-based fragment screen of Novartis' fragment collection resulted in the identifica
54 ith the HDAC inhibitor LBH589 (Panobinostat, Novartis, Germany); levels of proliferation, apoptosis,
55                           More recently, GNF/Novartis, GSK, and others have employed the same approac
56  and U01NS077352; NIH grant P50HD103526; and Novartis IIT grant AFQ056X2201T for provision of AFQ056.
57 -4-ylamino]-N-met hylbenzamide, TAE226) from Novartis, Inc.
58        KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synth
59 s the evolution of the screening deck at the Novartis Institutes for BioMedical Research (NIBR).
60    Jose M. Carballido, Executive Director at Novartis Institutes for BioMedical Research, and Pere Sa
61 versity and Inclusion (D&I) globally for the Novartis Institutes for BioMedical Research, which is th
62 s in various stages of deployment within the Novartis Institutes for BioMedical Research.
63        Sandoz International (a subsidiary of Novartis International).
64 leagues shows that deferasirox (DFX; Exjade, Novartis) is not inferior to deferoxamine (DFO; Desferal
65 rmany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisatio
66                             In October 2019, Novartis launched brolucizumab, a single-chain variable
67 el, Accommodations, Expenses; Advisory Board Novartis: Membership on an entity's Board of Directors o
68  studies in the treated patients was Impact (Novartis/Nestle), which contains omega-3 fatty acids, ar
69 randomized to receive either the IMN Impact (Novartis Nutrition), an enteral feed supplemented with a
70 ependent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respe
71  of Directors or advisory committees; 3SBIO, Novartis: Other: Travel, accomodations, expenses.
72 edback that was obtained from 35 chemists at Novartis over the course of several months.
73                                    Using the Novartis-Oxford multiple sclerosis (NO.MS) data pool spa
74                     Two 30-mug doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin) were admini
75  Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases
76 , Switzerland) versus ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) for neovascular
77     We tested the effect of everolimus (RAD, Novartis Pharma AG, Basel, Switzerland) on human PTLD-de
78                 In contrast to our report on Novartis Pharma APP23 Tg mice, which maintain high level
79 of AML were treated with PSC 833 (Valspodar; Novartis Pharmaceutical Corporation, East Hanover, NJ),
80                       Treatment with LAQ824 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic ac
81                                              Novartis Pharmaceuticals and Pfizer Inc.
82                                              Novartis Pharmaceuticals and Secura Bio.
83 Institute, National Clinical Trials Network, Novartis Pharmaceuticals Corporation, and The Hope Found
84 medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.
85 inhibitor STI571 (formerly called CGP57148B, Novartis Pharmaceuticals) inhibits BCR/ABL, TEL/ABL, and
86 le-center trial ( NCT02491281 ; sponsored by Novartis Pharmaceuticals), 28 patients with knee OA were
87 ; CT1418 (Celltech Therapeutics); CGS27023A (Novartis Pharmaceuticals); and RO31-9790 (Roche), with I
88                                              Novartis Pharmaceuticals, AirPROM project, and the UK Na
89 ancer Foundation, National Cancer Institute, Novartis Pharmaceuticals, and Merck.
90                                      AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent
91 tis Pharmaceuticals, Hanover, NJ) (Zortress; Novartis Pharmaceuticals, Basel, Switzerland) is intende
92 r, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly
93 herapy, such as the use of STI-571 (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatmen
94 xample, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown
95 of rapamycin inhibitor everolimus (Certican; Novartis Pharmaceuticals, Hanover, NJ) (Zortress; Novart
96                                              Novartis Pharmaceuticals, the Indiana University Simon C
97        Primary Funding Source: Genentech and Novartis Pharmaceuticals.
98  newer formulations of cyclosporine, Neoral (Novartis Pharmaceuticals; Basle, Switzerland), and other
99             H2020 European Research Council, Novartis Pharmacy B V Oncology Europe, Amgen, BMS/Celgen
100                         Novartis Access is a Novartis programme that offers a portfolio of non-commun
101                    Medical Research Council, Novartis, Renal Association, Kidney Research UK.
102                     In this issue, a team at Novartis reports on the identification of the first dire
103  from the Roche and Genomic Institute of the Novartis Research Foundation SNP databases.
104 / Celgene: Consultancy; Incyte: Consultancy; Novartis: Research Funding.
105 ultiple Sclerosis Alliance, Biogen, Celgene, Novartis, Roche.
106 evidence generated by this study will inform Novartis's efforts to improve their programme going forw
107                  Cancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Council (Lond
108 ancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIH
109                    Medical Research Council, Novartis, Schering Health Care, Chugai, Pharmion, Celgen
110       Medical Research Council (London, UK), Novartis, Schering Health Care, Chugai, Pharmion, Celgen
111 ), with unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgen
112 ite in EED discovered by in-house screening, Novartis scientists have now produced a compound that sh
113                              A search of the Novartis Secukinumab Compound Pool Database was conducte
114              Company-sponsored (Genentech or Novartis) studies in DME completed as of December 31, 20
115  for these domains as well as integrated the Novartis SymAtlas2 dataset for both human and mouse whic
116 g Center, Weiss Family Kidney Research Fund, Novartis, The Sidney Kimmel Center for Prostate and Urol
117 ciety of Great Britain and Northern Ireland, Novartis, UK National Institute for Health Research (NIH
118 kinase inhibitor imatinib mesylate (Gleevec, Novartis) ultimately led to the discovery of the FIP1L1-
119                                              Novartis, United States National Cancer Institute, Inter
120                                              Novartis Vaccines and Diagnostics division (now part of
121                                              Novartis Vaccines and Diagnostics division, now part of
122 m and the oil-in-water-based emulsions MF59 (Novartis Vaccines and Diagnostics), AS03 and AS04 (Glaxo
123 MF59-adjuvanted trivalent influenza vaccine (Novartis Vaccines and Diagnostics, Siena, Italy) has bee
124 ine (serotypes Ia, Ib, and III, with CRM197 [Novartis Vaccines, Siena, Italy]) intramuscularly at 24-
125 a novel synthetic Smo inhibitor, NVP-LDE225 (Novartis), which decreased MM cell viability by inducing
126 ia drug STI571 [imatinib mesylate (Gleevec); Novartis], which potently and selectively blocks Abl kin

 
Page Top